Ozone as adjuvant support in the treatment of COVID-19 : A preliminary report of probiozovid trial
© 2020 Wiley Periodicals LLC..
The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID-19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen-ozone administration in the early control of disease progression in patients with COVID-19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double-arm trial enrolling patient with COVID-19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone-autohemotherapy group (14) and control group (14). The procedure consisted in a daily double-treatment with systemic Oxygen-ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal-intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7-14 days of follow up. Thirty-day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone-autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID-19, did not report any toxicity.
| Errataetall: |
CommentIn: J Med Virol. 2021 May;93(5):2580-2582. - PMID 33503267 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of medical virology - 93(2021), 4 vom: 24. Apr., Seite 2210-2220 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Araimo, Fabio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
66H7ZZK23N |
|---|
| Anmerkungen: |
Date Completed 19.03.2021 Date Revised 07.12.2022 published: Print-Electronic CommentIn: J Med Virol. 2021 May;93(5):2580-2582. - PMID 33503267 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.26636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316806234 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316806234 | ||
| 003 | DE-627 | ||
| 005 | 20231225161855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.26636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316806234 | ||
| 035 | |a (NLM)33111980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Araimo, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ozone as adjuvant support in the treatment of COVID-19 |b A preliminary report of probiozovid trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Med Virol. 2021 May;93(5):2580-2582. - PMID 33503267 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID-19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen-ozone administration in the early control of disease progression in patients with COVID-19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double-arm trial enrolling patient with COVID-19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone-autohemotherapy group (14) and control group (14). The procedure consisted in a daily double-treatment with systemic Oxygen-ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal-intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7-14 days of follow up. Thirty-day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone-autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID-19, did not report any toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a autohemotherapy | |
| 650 | 4 | |a ozone | |
| 650 | 4 | |a respiratory insufficiency | |
| 650 | 7 | |a Ozone |2 NLM | |
| 650 | 7 | |a 66H7ZZK23N |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Imperiale, Carmela |e verfasserin |4 aut | |
| 700 | 1 | |a Tordiglione, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Borrazzo, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Alessandri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santinelli, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Innocenti, Giuseppe Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Pinacchio, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Mauro, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Recchia, Gregorio Egidio |e verfasserin |4 aut | |
| 700 | 1 | |a Zancla, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Calò, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Poscia, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ruberto, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a d'Ettorre, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Bilotta, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 4 vom: 24. Apr., Seite 2210-2220 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:4 |g day:24 |g month:04 |g pages:2210-2220 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 4 |b 24 |c 04 |h 2210-2220 | ||